Movement Alert｜Liquidia Technologies Rises 15.51% in Regular Trading, Trading at $63.95

Market Focus06-04

On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.

Within the Pharmacy sector where Liquidia Technologies belongs, individual stocks showed broad gains. Among them, Eli Lilly up 5.16%, Johnson & Johnson up 1.44%, Novo-Nordisk up 5.17%, Merck up 3.04%, Pfizer up 1.32%.

Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil, and Remodulin. The company leverages its proprietary PRINT particle engineering technology platform to precisely produce uniform drug particles for improved therapeutic performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144587391?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144587391","market":"us","top_or_hot":-1,"title":"Movement Alert｜Liquidia Technologies Rises 15.51% in Regular Trading, Trading at $63.95","media":"Market Focus","content":"<p><p>On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.</p><p>Within the Pharmacy sector where Liquidia Technologies belongs, individual stocks showed broad gains. Among them, Eli Lilly up 5.16%, Johnson & Johnson up 1.44%, Novo-Nordisk up 5.17%, Merck up 3.04%, Pfizer up 1.32%.</p><p>Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil, and Remodulin. The company leverages its proprietary PRINT particle engineering technology platform to precisely produce uniform drug particles for improved therapeutic performance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Liquidia Technologies Rises 15.51% in Regular Trading, Trading at $63.95</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Liquidia Technologies Rises 15.51% in Regular Trading, Trading at $63.95\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.</p><p>Within the Pharmacy sector where Liquidia Technologies belongs, individual stocks showed broad gains. Among them, Eli Lilly up 5.16%, Johnson & Johnson up 1.44%, Novo-Nordisk up 5.17%, Merck up 3.04%, Pfizer up 1.32%.</p><p>Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil, and Remodulin. The company leverages its proprietary PRINT particle engineering technology platform to precisely produce uniform drug particles for improved therapeutic performance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1144587391","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144587391","pubTimestamp":1780586051,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.Within the Pharmacy sector where Liquidia Technologies belongs,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc"},"translate_title":"走势提示|Liquidia Technologies常规交易上涨15.51%，报63.95美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"On June 4, Liquidia Technologies rose 15.51% in regular trading, trading at $63.95 USD/share, with trading volume of $112 million.Within the Pharmacy sector where Liquidia Technologies belongs, individual stocks showed broad gains. Among them, Eli Lilly up 5.16%, Johnson & Johnson up 1.44%, Novo-Nordisk up 5.17%, Merck up 3.04%, Pfizer up 1.32%.Liquidia Corporation is a biopharmaceutical company focused on the development, manufacturing, and commercialization of products for unmet patient needs, with current emphasis on pulmonary arterial hypertension treatment. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil, and Remodulin. The company leverages its proprietary PRINT particle engineering technology platform to precisely produce uniform drug particles for improved therapeutic performance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144587391","isCrawlerRequest":true}